Stockscreener 앱 받기
0.00
100.00%
-41.03
시간 외 거래:
41.06
41.06
+
Apellis Pharmaceuticals Inc 주식(APLS)의 최신 뉴스
Layoff Tracker: Merck adds 53 jobs to New Jersey chopping block - biospace.com
Statements about clinical trials not ‘half-truths,’ panel finds - Rhode Island Lawyers Weekly
Apellis (APLS) Latest Quarter: EPS Beats Its Estimate for the Current Session ; Share Reaction Is Left UnclassifiedEarnings Manipulation Risk - vinanet.vn
Apellis Pharmaceuticals, Inc. Revenue Breakdown – LS:A2JAAW - TradingView
1st Circ. Says Apellis Disclosures Weren't 'Half-Truths' - Law360
Apellis (APLS) Quarterly Figures: The Bottom-Line Figure Outpaces Its Comparison in the Latest Reading ; The Review Focuses on Reported ResultsEarnings Deceleration Risk - vinanet.vn
Wolfe Research Issues Rare Double Upgrade for Biogen and AbbVie, Setting $300 Targets - finance.biggo.com
new drugs are rewriting Biogen’s storyNews Freedom Broker - fbroker.kz
Biogen is scaling back acquisitions and will focus on its existing pipeline - medwatch.com
Biogen flips '26 guidance from expected decline to sales increase - Fierce Pharma
Biogen beats quarterly estimates as newer drugs drive growth - 1470 & 100.3 WMBD
Apellis Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Biogen bets newly acquired Apellis can paper over Leqembi's disappointing sales into 2027 - Endpoints News
Biotech's takeover boom may be running out of buyers - Yahoo Finance UK
Biogen trims Apellis pipeline and R&D team after $5.6bn takeover - MSN
Philip Ferrone, MD, to join Apellis Pharmaceuticals as Chief Medical Retina Advisor - Ophthalmology Times
Biogen projects $164M hit to Q2 results from R&D deals and acquisitions - MSN
Price to earnings forward of Apellis Pharmaceuticals, Inc. – LS:A2JAAW - TradingView
Operating cash flow per share of Apellis Pharmaceuticals, Inc. – LS:A2JAAW - TradingView
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout - MSN
Apellis Pharmaceuticals, Inc. Actuals & Estimates (LS:A2JAAW) - TradingView
A2JAAW Forecast — Price Target — Prediction for 2027 - TradingView
After buying Apellis for $5.6B, Biogen is cutting most of its pipeline work - Endpoints News
How Apellis Pharmaceuticals Inc. (APLS) Affects Rotational Strategy Timing - Stock Traders Daily
Apellis Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Sullivan Timothy Eugene - Moomoo
Biogen adds more immune drugs in $1B buyout of secretive startup RayThera - finance.yahoo.com
Apellis Pharmaceuticals Inc (APLS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BIIB Stock: Biogen Strengthens Immunology Pipeline In Up To $1B RayThera Deal - Yahoo Finance
Apellis Pharmaceuticals Inc (APLS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Apellis Pharmaceuticals Inc (APLS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Apellis Pharmaceuticals Inc (APLS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
EBIT per share of Apellis Pharmaceuticals, Inc. – LS:A2JAAW - TradingView
Apellis Pharmaceuticals, Inc. (APLS) tops Q1 earnings and revenue estimates - MSN
Biogen (NASDAQ: BIIB) deems Apellis acquisition not significant - Stock Titan
Apellis Pharmaceuticals | SC TO-C: Written communication relating to an issuer or third party tender offer - Moomoo
Apellis Pharmaceuticals (APLS) moves 135.4% higher: Will this strength last? - MSN
Apellis (APLS) Amendment: Morgan Stanley Reports - Stock Titan
Number of shareholders of Apellis Pharmaceuticals, Inc. – BX:APLS - TradingView
APLS Technical Analysis & Stock Price Forecast - Intellectia AI
JP Morgan Maintains Apellis Pharmaceuticals (APLS) Overweight Recommendation - MSN
Apellis Pharmaceuticals (APLS) Holds Steady Near Support as Investors Weigh Catalyst PipelineTotal Put Call - po-news-eg.net
Biotech Growth Trust Portfolio Company Apellis To Be Acquired By Biogen - DirectorsTalk Interviews
[15-12G] Apellis Pharmaceuticals, Inc. SEC Filing - Stock Titan
Leqembi Isn't Enough To Save Biogen Momentum (Rating Downgrade) - Seeking Alpha
Apellis soars on Biogen deal as biopharma index trails the market - BioWorld News
Biogen lands two fast-growing drugs in blockbuster Apellis deal - MSN
Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains? - Eastern Progress
Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left - TechStock²
Apellis Pharmaceuticals (NASDAQ:APLS) Shines in Navellier’s Growth Screen With Strong Earnings and Revenue Momentum - ChartMill
0.00%
0.81%
자본화:
|
볼륨(24시간):